Cardio3 snaps up valve access business
The Belgian biotechnology company Cardio3 BioSciences acquired a device maker that specializes in heart access technologies for an undisclosed amount.
CorQuest is developing technologies that facilitate access directly to a patient's left atrium for treating mitral valve disorders and structural heart disease. The technologies allow cardiac surgeons to use a minimally invasive approach to deliver existing therapeutic devices. Cardio3 BioSciences sees the technology as complementary to its catheter and sheath delivery platforms.
The technology has yet to be approved in Europe or the U.S. The companies have a target date of late 2016 to obtain CE mark.
CorQuest also offers a line of medical devices and implants for treating structural heart diseases.
Cardio3 BioSciences is based in Mont-Saint-Guibert and CorQuest is in Miami.